{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:56:20Z","timestamp":1791608180085,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003385","name":"Georg-August-Universit\u00e4t G\u00f6ttingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003385","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract\u00a0<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To investigate the lower visual acuity threshold for recommending intravitreal injection therapy (IVI). The lower limit of 1.3 logMAR best-corrected visual acuity (BCVA) was adopted in 2006 and has been maintained since then.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective study, data from patients with a logMAR BCVA\u2009\u2264\u20091.3 and 24\u00a0months follow-up were analysed. We included patients with neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), or retinal vein occlusion (RVO).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The data from 164 patients (nAMD: 107; DME: 15; RVO: 42) were analysed. We observed a significant improvement at all time intervals (0 to 6, 6 to 12, 12 to 18, and 18 to 24\u00a0months after initiating IVI) compared to baseline. Across all indications, median BCVA improved from 1.4 to 1.0 within the first 6\u00a0months and remained stable within 24\u00a0months. Patients received a median of 5 and 10 injections within 6 and 24\u00a0months, respectively. Median foveal retinal thickness was 594.5\u00a0\u03bcm at baseline and dropped to 244.5\u00a0\u03bcm, 235.5\u00a0\u00b5m, 183\u00a0\u00b5m, and 180\u00a0\u00b5m during the four consecutive time intervals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients with nAMD, DME, and RVO with poor baseline BCVA may also benefit from intravitreal therapy with VEGF-inhibitors. In the present study, we observed functional and morphological improvement over 2\u00a0years irrespective of the underlying macular disease. Those patients should not be excluded from therapy.<\/jats:p>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00417-023-05989-3","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T23:51:13Z","timestamp":1679874673000},"page":"2421-2429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Benefit of intravitreal injections in patients with sub-threshold baseline visual acuity: a retrospective single-centre study"],"prefix":"10.1007","volume":"261","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8639-2046","authenticated-orcid":false,"given":"Nina-Antonia","family":"Grimm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Fahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"K\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Take","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peer","family":"Lauermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Nguyen-Hoehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hoerauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Feltgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bemme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"issue":"5","key":"5989_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s12325-016-0332-7","volume":"33","author":"S Androudi","year":"2016","unstructured":"Androudi S, Dastiridou A, Pharmakakis N et al (2016) Guidelines for the management of wet age-related macular degeneration: recommendations from a panel of Greek experts. Adv Ther 33(5):715\u2013726","journal-title":"Adv Ther"},{"issue":"1","key":"5989_CR2","first-page":"120","volume":"34","author":"A Arditi","year":"1993","unstructured":"Arditi A, Cagenello R (1993) On the statistical reliability of letter-chart visual acuity measurements. Invest Ophthalmol Vis Sci 34(1):120\u2013129","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"5989_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0002-9394(14)75575-8","volume":"109","author":"SR Bennett","year":"1990","unstructured":"Bennett SR, Folk JC, Blodi CF, Klugman M (1990) Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 109(1):33\u201337","journal-title":"Am J Ophthalmol"},{"key":"5989_CR4","first-page":"635","volume":"109","author":"S Bopp","year":"2012","unstructured":"Bopp S (2012) Subretinal hemorrhage. Natural course and staging. Ophthalmol Z Dtsch Ophthalmol Ges 109:635\u2013643","journal-title":"Ophthalmol Z Dtsch Ophthalmol Ges"},{"key":"5989_CR5","doi-asserted-by":"crossref","unstructured":"Boyer DS, Yoon YH, Belfort R Jr et al (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121(10):1904\u201314","DOI":"10.1016\/j.ophtha.2014.04.024"},{"key":"5989_CR6","doi-asserted-by":"crossref","unstructured":"Brown DM, Kaiser PK, Michels M et. al. ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355, 1432\u20131444","DOI":"10.1056\/NEJMoa062655"},{"key":"5989_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57\u201365","journal-title":"Ophthalmology"},{"issue":"6","key":"5989_CR8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RPCRUISE, Investigators, et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117(6):1124\u20131133","journal-title":"Ophthalmology"},{"issue":"3","key":"5989_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","volume":"155","author":"DM Brown","year":"2013","unstructured":"Brown DM, Heier JS, Clark WL et al (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155(3):429\u2013437","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"5989_CR10","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown DM, Nguyen QD, Marcus DM, RIDE and RISE Research Group et al (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120(10):2013\u20132022","journal-title":"Ophthalmology"},{"issue":"10","key":"5989_CR11","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","volume":"122","author":"DM Brown","year":"2015","unstructured":"Brown DM, Schmidt-Erfurth U, Do DV et al (2015) Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 122(10):2044\u20132052","journal-title":"Ophthalmology"},{"issue":"5","key":"5989_CR12","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1111\/rssb.12222","volume":"79","author":"E Brunner","year":"2017","unstructured":"Brunner E, Konietschke F, Pauly M, Puri ML (2017) Rank-based procedures in factorial designs: hypotheses about non-parametric treatment effects. J Royal Stat Soc: Ser B (Statistical Methodology) 79(5):1463\u20131485","journal-title":"J Royal Stat Soc: Ser B (Statistical Methodology)"},{"issue":"6","key":"5989_CR13","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro PA, Heier JS, Feiner L et al (2010) BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion six-month primary end point results of a phase III study. Ophthalmology 117(6):1102\u20131112","journal-title":"Ophthalmology"},{"issue":"2","key":"5989_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","volume":"123","author":"WL Clark","year":"2016","unstructured":"Clark WL, Boyer DS, Heier JS et al (2016) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 123(2):330\u2013336","journal-title":"Ophthalmology"},{"key":"5989_CR15","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00347-020-01117-2","volume":"117","author":"Deutsche OphthalmologischeGesellschaft (DOG)","year":"2020","unstructured":"Deutsche OphthalmologischeGesellschaft (DOG), RetinologischeGesellschaft e.\u202fV. (RG), Berufsverband der Augen\u00e4rzteDeutschlands e.\u202fV. (BVA) (2020) Statement of the German Ophthalmological Society (DOG), the Retinological Society (RG) and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration\u202f: status February 2020. Ophthalmologe 117:746\u2013754","journal-title":"Ophthalmologe"},{"key":"5989_CR16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00347-019-01015-2","volume":"117","author":"Deutsche OphthalmologischeGesellschaft (DOG)","year":"2020","unstructured":"Deutsche OphthalmologischeGesellschaft (DOG), RetinologischeGesellschaft e.\u202fV. (RG), Berufsverband der Augen\u00e4rzteDeutschlands e.\u202fV (2020) Statement of the German Ophthalmological Society, the Retinological Society and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema\u202f: situation August 2019. Ophthalmologe 117:218\u2013247","journal-title":"Ophthalmologe"},{"issue":"1","key":"5989_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2019","unstructured":"Dugel PU, Koh A, Ogura Y et al (2019) HAWK and HARRIER Study Investigators. HAWK and HARRIER phase 3 multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127(1):72\u201384","journal-title":"Ophthalmology"},{"key":"5989_CR18","doi-asserted-by":"crossref","unstructured":"Dugel PU, Koh A, Ogura Y et al (2020) HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127(1):72\u201384","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"5989_CR19","doi-asserted-by":"crossref","unstructured":"Dugel PU, Singh RP, Koh A et al (2020) HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128(1):89\u201399","DOI":"10.1016\/j.ophtha.2019.04.017"},{"issue":"1","key":"5989_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A et al (2021) HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128(1):89\u201399","journal-title":"Ophthalmology"},{"key":"5989_CR21","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00347-012-2660-6","volume":"109","author":"Germany Ophthalmology Society, Retina Society, Professional Asociation of German Ophthalmologists","year":"2012","unstructured":"Germany Ophthalmology Society, Retina Society, Professional Asociation of German Ophthalmologists (2012) Statement of the German Ophthalmology Society, the Retina Society and the Professional Association of German Ophthalmologists for the treatment of macular edema in retinal vein occlusion: therapeutic strategies. Ophthalmologe 109:818\u2013831","journal-title":"Ophthalmologe"},{"issue":"12","key":"5989_CR22","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) VIEW 1 and VIEW 2 Study Groups Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537\u20132548","journal-title":"Ophthalmology"},{"issue":"7","key":"5989_CR23","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","volume":"121","author":"JS Heier","year":"2014","unstructured":"Heier JS, Clark WL, Boyer DS et al (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 121(7):1414\u20131420","journal-title":"Ophthalmology"},{"issue":"11","key":"5989_CR24","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Heier","year":"2016","unstructured":"Heier JS, Korobelnik JF, Brown DM et al (2016) Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 123(11):2376\u20132385","journal-title":"Ophthalmology"},{"issue":"10326","key":"5989_CR25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C et al (2022) TENAYA and LUCERNE Investigators Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399(10326):729\u2013740","journal-title":"Lancet"},{"issue":"7","key":"5989_CR26","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00347-016-0224-x","volume":"113","author":"B Heimes","year":"2016","unstructured":"Heimes B, Schick T, Brinkmann CK et al (2016) Design des ORCA-Moduls der OCEAN-Studie: evaluierung der SD-OCT-Befunderhebung in der t\u00e4glichen Praxisroutine [Design of the ORCA module in the OCEAN study: evaluation of SD-OCT results in daily routine practice]. Ophthalmologe 113(7):570\u2013580","journal-title":"Ophthalmologe"},{"issue":"3","key":"5989_CR27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","volume":"97","author":"FG Holz","year":"2013","unstructured":"Holz FG, Roider J, Ogura Y et al (2013) VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 97(3):278\u2013284","journal-title":"Br J Ophthalmol"},{"key":"5989_CR28","doi-asserted-by":"crossref","unstructured":"Korobelnik JF, Do DV, Schmidt-Erfurth U et al (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121(11):2247\u201354","DOI":"10.1016\/j.ophtha.2014.05.006"},{"issue":"1","key":"5989_CR29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","volume":"121","author":"JF Korobelnik","year":"2013","unstructured":"Korobelnik JF, Holz FG, Roider J et al (2013) GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 121(1):202\u2013208","journal-title":"Ophthalmology"},{"key":"5989_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00417-008-0926-0","volume":"247","author":"C Lange","year":"2009","unstructured":"Lange C, Feltgen N, Junker B, et. al. (2009) Resolving the clinical acuity categories \u201chand motion\u201d and \u201ccounting fingers\u201d using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol 247:137\u2013142","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"5989_CR31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00417-003-0707-8","volume":"241","author":"KL Loumann","year":"2003","unstructured":"Loumann KL (2003) Visual acuity testing in diabetic subjects: the decimal progression chart versus the Freiburg visual acuity test. Graefes Arch Clin Exp Ophthalmol 241(8):615\u2013618","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"5989_CR32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","volume":"118","author":"P Mitchell","year":"2011","unstructured":"Mitchell P, Bandello F, Schmidt-Erfurth U et al (2011) RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 118(4):615\u201325","journal-title":"Ophthalmology."},{"issue":"4","key":"5989_CR33","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM et al (2012) RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119(4):789\u2013801","journal-title":"Ophthalmology"},{"issue":"5","key":"5989_CR34","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ajo.2014.07.027","volume":"158","author":"Y Ogura","year":"2014","unstructured":"Ogura Y, Roider J, Korobelnik JF et al (2014) GALILEO Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 158(5):1032\u20138","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"5989_CR35","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1055\/s-2008-1034969","volume":"213","author":"W Radner","year":"1998","unstructured":"Radner W, Willinger U, Obermayer W et al (1998) Eine neue Lesetafel zur gleichzeitigen Bestimmung von Lesevisus und Lesegeschwindigkeit [A new reading chart for simultaneous determination of reading vision and reading speed]. Klin Monbl Augenheilkd 213(3):174\u2013181","journal-title":"Klin Monbl Augenheilkd"},{"issue":"4","key":"5989_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.oret.2021.12.007","volume":"6","author":"S Riedl","year":"2022","unstructured":"Riedl S, Vogl WD, Waldstein SM et al (2022) Impact of intra- and subretinal fluid on vision based on volume quantification in the HARBOR trial. Ophthalmol Retina 6(4):291\u2013297","journal-title":"Ophthalmol Retina"},{"key":"5989_CR37","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) MARINA Study Group: ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"5989_CR38","doi-asserted-by":"crossref","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A et al (2014) European Society of Retina Specialists. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98(9):1144\u201367","DOI":"10.1136\/bjophthalmol-2014-305702"},{"key":"5989_CR39","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1167\/iovs.05-0981","volume":"47","author":"K Schulze-Bonsel","year":"2006","unstructured":"Schulze-Bonsel K, Feltgen N, Burau H et al (2006) Visual Acuities \u201cHand Motion\u201d and \u201cCounting Fingers\u201d can be quantified with the Freiburg visual acuity test. Invest Ophthalmol Vis Sci 47:1236","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"5989_CR40","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s00347-020-01218-y","volume":"118","author":"P Take","year":"2021","unstructured":"Take P, Dittmann CA, Mackerodt L et al (2021) Das modifizierte treat-and-extend-schema mit injektionsbl\u00f6cken in der IVOM-therapie: retrospektive analyse aus der t\u00e4glichen klinischen anwendung [The modified treat and extend scheme with injection blocks in intravitreal injection treatment\u202f: retrospective analysis from the routine clinical application]. Ophthalmologe 118(6):578\u2013586","journal-title":"Ophthalmologe"},{"issue":"10326","key":"5989_CR41","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP et al (2022) YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 399(10326):741\u2013755","journal-title":"Lancet"},{"key":"5989_CR42","unstructured":"Wolfram C, Pfeiffer N (2012)Wei\u00dfbuch zur Situation der ophthalmologischen Versorgung in Deutschland,M\u00fcnchen"},{"key":"5989_CR43","doi-asserted-by":"crossref","unstructured":"Ziemssen F, Eter N, Fauser S et al (2015) Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany. Ophthalmologe 112(3):246\u201354","DOI":"10.1007\/s00347-014-3217-7"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-05989-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-05989-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-05989-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T09:05:46Z","timestamp":1690275946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-05989-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5989"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-05989-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"assertion":[{"value":"22 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study concurs with the 1964 Helsinki declaration and its later amendments, and was approved by our institutional ethics committee of the university of Goettingen (application number is 6\/11\/20).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Nina-Antonia Grimm: Speaker: Novartis AG, Bayer AG, OD-OS GmbH.Sarah Fahimi: No conflict of interest.Fabian K\u00fcck: No conflict of interest.Patricia Take: No conflict of interest.Peer Lauermann: No conflict of interest.Anna Nguyen-Hoehl: No conflict of interest.Hans Hoerauf: Consultant: Novartis, Roche Allergan; Speaker: Novartis, Roche, Allergan, Biogen, Alcon, Heidelberg Engeneering; Research projects: Bayer Heath Care, Novartis, Allergan, chengdu Khanghong, Biotec, Hoffmann LaRoche, Samsung, Benevolent, Regeneron, Santen GmbH, Boehringer Ingelheim, Mylan, Appelis; Owner interest in medical products: Novartis, Bayer, 3\u00a0M, Roche, Johnson&Johnson, Mediatronis, Abbvie, Pfizer.Nicolas Feltgen: Consultant: Alimera Sciences, Novartis, Roche; Speaker: Allergan, Alimera, Bayer, Heidelberg Engineering, Novartis, Roche.Sebastian Bemme: Speaker: Novartis AG, Bayer AG; Research grant: Novartis AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}